BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with

•

Newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML). (1)

•

Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy. (1)

•

Newly-diagnosed chronic phase Ph+ CML: 400 mg orally once daily with food. (2.1)

•

Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy: 500 mg orally once daily with food. (2.1)

•

Consider dose escalation by increments of 100 mg once daily to a maximum of 600 mg daily in patients who do not reach complete hematologic, cytogenetic, or molecular response and do not have Grade 3 or greater adverse reactions. (2.2)

•

Adjust dosage for toxicity and organ impairment (2)

Tablets: 100 mg, 400 mg, and 500 mg. (3)

Hypersensitivity to BOSULIF. (4)

•

Gastrointestinal Toxicity: Monitor and manage as necessary. Withhold, dose reduce, or discontinue BOSULIF. (2.3, 5.1)

•

Myelosuppression: Monitor blood counts and manage as necessary. (2.4, 5.2)

•

Hepatic Toxicity: Monitor liver enzymes at least monthly for the first 3 months and as needed. Withhold, dose reduce, or discontinue BOSULIF. (2.3, 5.3)

•

Cardiovascular Toxicity: Monitor and manage as necessary. (5.4)

•

Fluid Retention: Monitor patients and manage using standard of care treatment. Withhold, dose reduce, or discontinue BOSULIF. (2.3, 5.5)

•

Renal Toxicity: Monitor patients for renal function at baseline and during therapy with BOSULIF. (5.6)

•

Embryo-Fetal Toxicity: BOSULIF can cause fetal harm. Advise female patients of reproductive potential of potential risk to a fetus and to use effective contraception. (5.7)

•

Most common adverse reactions (≥20%), in patients with CML are diarrhea, rash, nausea, abdominal pain, vomiting, fatigue, hepatic dysfunction, respiratory tract infection, pyrexia, and headache. The most common laboratory abnormalities (≥20%) are creatinine increased, hemoglobin decreased, lymphocyte count decreased, platelets decreased, ALT increased, calcium decreased, white blood cell count decreased, absolute neutrophil count decreased, AST increased, glucose increased, phosphorus decreased, urate increased, alkaline phosphatase increased, lipase increased, creatine kinase increased, and amylase increased. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

•

Strong and Moderate CYP3A Inhibitors: Avoid concomitant use with BOSULIF. (7.1)

•

Strong CYP3A Inducers: Avoid concomitant use with BOSULIF. (7.1)

•

Proton Pump Inhibitors: Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors. (7.1)

Lactation: Advise women not to breastfeed. (8.2)